Yostra Labs is a medtech startup based in Bengaluru, India, that develops devices for diagnosing and managing diabetic foot and peripheral neuropathy for clinics and hospitals.

This Startup Deep Dive explains what Yostra Labs does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Yostra Labs in Brief

• What it is: Yostra Labs is an Indian Diabetic foot medtech company based in Bengaluru.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Yostra Labs offers products for the diagnosis and management of peripheral neuropathy and complications such as foot ulcers.
• It focuses on diabetic foot, a diabetes complication that reports describe as widely neglected.
• Its devices are used in clinics, private and government hospitals and diagnostics centres in India.
• Funding: reports differ: one database lists about $580K over 5 rounds (reported); the 2022 seed was Rs 4 crore (reported).

Yostra Labs Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Yostra Labs?

Yostra Labs operates in the Diabetic foot medtech space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Yostra Labs.

• Yostra Labs offers products for the diagnosis and management of peripheral neuropathy and complications such as foot ulcers.
• It focuses on diabetic foot, a diabetes complication that reports describe as widely neglected.
• Its devices are used in clinics, private and government hospitals and diagnostics centres in India.

The Origin Story of Yostra Labs

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Vinayak Nandalike, Mohan Rao, Sanjay Sharma, Dr. Maruthy.
• Reports say the company was founded in 2014; reports differ slightly on the founder list, with one 2017 report naming Vinayak Nandalike, Maruthy KN, Ram Mohan Rao and Sanjay Sharma.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Diabetic foot medtech sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• January 2017: funding from Marico Innovation Foundation and Villgro, amount undisclosed (reported).
• August 2022: raised Rs 4 crore seed round led by Indian Angel Network (reported).

Yostra Labs Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• January 2017: undisclosed amount from Marico Innovation Foundation and Villgro (reported).
• August 2022: Rs 4 crore seed led by Indian Angel Network, with Villgro Innovations Foundation and Centre for Cellular and Molecular Platforms (reported).

How Does Yostra Labs Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue sources: The exact revenue mix of Yostra Labs is not disclosed in public sources reviewed.
• What to look for: Recurring contracts, repeat customers, gross margin trend and payback on customer acquisition.

The Numbers: Yostra Labs Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Devices have screened over 40,000 patients (company-stated, as of August 2022).

Market Opportunity for Yostra Labs

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Diabetic foot is described as a neglected diabetes complication with mortality said to be higher than cancer.

Technology and Product at Yostra Labs

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Core capability: Public detail on Yostra Labs’s technology stack is limited beyond company-stated descriptions.
• Assessment lens: clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

Team and Culture at Yostra Labs

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Vinayak Nandalike is the founder quoted in the 2022 funding announcement.

Yostra Labs Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

• Direct competitors of Yostra Labs vary by product line; a verified rival comparison was not available from public sources.
• What to compare: Product readiness, pricing, customer base, funding runway and regulatory standing.

Risks and Challenges for Yostra Labs

• Disclosed funding is small (Rs 4 crore seed in 2022), and no later round was found.
• No revenue or profit figures were found in sources read.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Yostra Labs Growth Outlook: What to Watch

• Seed proceeds are earmarked for expanding in-house sales and marketing teams, widening market reach, commercialising the product portfolio, optimising bill of materials and scaling production.
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Yostra Labs can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Yostra Labs Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Yostra Labs

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Yostra Labs.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Yostra Labs

Studying a company in the Diabetic foot medtech space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Yostra Labs.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Yostra Labs as a Startup

• Customer clarity: Can Yostra Labs name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Yostra Labs is part of India’s growing Diabetic foot medtech ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Yostra Labs FAQs: Frequently Asked Questions

What is Yostra Labs?

Yostra Labs is a medtech startup based in Bengaluru, India, that develops devices for diagnosing and managing diabetic foot and peripheral neuropathy for clinics and hospitals. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Yostra Labs?

Yostra Labs was founded by Vinayak Nandalike, Mohan Rao, Sanjay Sharma, Dr. Maruthy, and the company reports a founding year of 2014.

How much funding has Yostra Labs raised?

reports differ: one database lists about $580K over 5 rounds (reported); the 2022 seed was Rs 4 crore (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Yostra Labs make money?

Yostra Labs earns revenue from its Diabetic foot medtech products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Yostra Labs?

Competitors of Yostra Labs depend on the specific product line. A verified comparison was not available, so see the evaluation checklist above.

What are the main risks for Yostra Labs?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Forus Health — Forus Health’s 3nethra devices reach 75+ countries | Astrogate Labs — Bengaluru startup building laser links for satellites. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.